Previous 10 | Next 10 |
A large part of a $5 billion bet that Gilead Sciences (NASDAQ: GILD) made in 2019 has fallen apart in late clinical-stage development. The bottom fell out from under ziritaxestat, a new drug candidate Gilead Sciences was developing in partnership with Galapagos (NASDAQ: GLPG) ...
Gainers: Bio-Path Holdings (BPTH) +253%.Cancer Genetics (CGIX) +74%.Torchlight Energy Resources (TRCH) +73%.CM Life Sciences (CMLF) +51%.India Globalization Capital (IGC) +42%.Anchiano Therapeutics (ANCN) +42%.The OLB Group (OLB) +41%.Sundial Growers (SNDL) +40%.Clever Lea...
Galapagos NV (GLPG) has lost ~15.3% in value so far today after the Belgium biotech and Gilead Sciences ([[GILD]] +0.8%) announced their decision to halt the ISABELA Phase 3 clinical studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis.The decision was...
Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the ...
Foster City, CA and Mechelen, Belgium, 10 February 2021, 15.00 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences (NASDAQ: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autota...
Mechelen, Belgium; 9 February 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc. Pursuant to Belgian transparency legislation 1 , Galapagos received a transpar...
Galapagos (GLPG) announces that the National Institute for Health and Care Excellence ((NICE)) has issued a final appraisal determination ((FAD)) recommending the use of the daily oral pill, Jyseleca (filgotinib) in England for the treatment of eligible adult patients with moderate ...
NOT FOR DISTRIBUTION IN THE UNITED KINGDOM NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis (RA) - aiming to avoid irreversible damage as early as possible 1 Mo...
Mechelen, Belgium; 11 January 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian transparency legislation 1 , Galapagos received a transparency notificat...
Mechelen, Belgium; 6 January 2021, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11-14, 2021. Onno van de Stolpe, CEO, will present on Thursday, January 14 at 15.10 CET (09:10 am EST). T...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...